Viehbacher: Sanofi, Genzyme have mutually beneficial qualities

04/8/2011 | Boston Globe (tiered subscription model), The

Sanofi-Aventis CEO Christopher A. Viehbacher said Genzyme's focus on patients and open partnerships are some of the characteristics that could benefit Sanofi, while the latter's global sales force and other resources could help Genzyme. Although there still are many business decisions to make, Viehbacher said, Sanofi plans to support the development of Genzyme's three drug candidates, including a treatment for Niemann-Pick disease, that have been halted after the firm focused its attention addressing manufacturing issues.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN